Cargando…
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)
BACKGROUND: This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcin...
Autores principales: | Ostwal, Vikas, Ramaswamy, Anant, Gota, Vikram, Bhargava, Prabhat G, Srinivas, Sujay, Shriyan, Bharati, Jadhav, Shraddha, Goel, Mahesh, Patkar, Shraddha, Mandavkar, Sarika, Naughane, Deepali, Daddi, Anuprita, Nashikkar, Chaitali, Shetty, Nitin, Ankathi, Suman Kumar, Banavali, Shripad D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914502/ https://www.ncbi.nlm.nih.gov/pubmed/35274724 http://dx.doi.org/10.1093/oncolo/oyab008 |
Ejemplares similares
-
Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
por: Harris, Caleb, et al.
Publicado: (2019) -
Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers
por: Ramaswamy, Anant, et al.
Publicado: (2018) -
Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
por: D’Souza, Anita, et al.
Publicado: (2020) -
Development of a New Tool to Assess the Quality of Life of Patients with Hand–Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study
por: Jagdish, Prathepa, et al.
Publicado: (2022) -
Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)